Although in other pathological contexts (i.e. glioblastoma, pancreatic and breast cancer, idiopathic pulmonary fibrosis) the integrin-mediated TGF-β1 activation is a well-known pharmacological axis and several compounds have been already included in clinical trials [19], the involvement of this molecular mechanism, as well as its inhibition, in hypertension-derived cardiac fibrosis has not been yet evaluated. Here, TGFB1 is linked to hypertensive disorder.